Low dose naltrexone (LDN), where naltrexone is used in doses approximately one-tenth those used for drug/alcohol rehabilitation purposes, is being used as an "off-label" treatment for certain immunologically-related disorders. The use of LDN for such diseases as cancer was first proposed by Ian Zagon, PhD, and LDN's broader clinical effects in humans were proposed by Bernard Bihari, MD.
In Milan, Italy, a sixth month trial with a low dose of the ...
more
Low dose naltrexone (LDN), where naltrexone is used in doses approximately one-tenth those used for drug/alcohol rehabilitation purposes, is being used as an "off-label" treatment for certain immunologically-related disorders. The use of LDN for such diseases as cancer was first proposed by Ian Zagon, PhD, and LDN's broader clinical effects in humans were proposed by Bernard Bihari, MD.
In Milan, Italy, a sixth month trial with a low dose of the opiate antagonist Naltrexone (LDN) was carried out in 40 patients with primary progressive multiple sclerosis (PPMS). It reported that neurological disability progressed in only one patient, and that a significant reduction of spasticity was measured at the end of the trial. It also reported that BE concentration increased during the trial, but that no association was found between OPRM1 variants and improvement of spasticity. There were two "major adverse events" and five dropouts from the trial, resulting in an extremely small sample group....
less
